# Trevi Therapeutics Inc. (TRVI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.26, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Trevi Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 7.6×**. The shares trade at 7.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.1%** (5-yr avg -14.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -23.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 31.9%**. Earnings per share rose 31.9%.

## Financial health
- **Current ratio: 19.66** (quick 19.66). Current assets cover the next year's liabilities 19.66 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Trevi Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 138.7%** (YTD 37.9%, 3-mo 29.5%). The shares are up 138.7% over twelve months including dividends.
- **From 52-week high: -14.6%** (132.0% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.14** (volatility 63%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TRVI · Page: https://foliofundamentals.com/stocks/trvi

Not investment advice.